Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
1-15 of 4483 results
Ultragenyx proposes to acquire Dimension Therapeutics
By PBR Staff Writer
Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138m, in cash at close to be effectuated via a tender offer.
Drug Research > Drug Discovery & Development > News
Mustang Bio announces expansion of CAR T pipeline into CD20-directed immunotherapies
Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Drug Research > Drug Discovery & Development > News
BMS to use Halozyme’s Enhanze technology to develop immuno-oncology medicines
By PBR Staff Writer
Bristol-Myers Squibb (BMS) has partnered with Halozyme Therapeutics for the development of immuno-oncology medicines.
Drug Research > Drug Discovery & Development > News
Berkeley Lights, Bayer partner for cell line development and antibody discovery
Berkeley Lights (BLI), a company dedicated to bringing to market transformational platforms for bio-pharmaceutical processes, has announced a strategic project with Bayer, focused on the innovation and acceleration of cell line development, antibody discovery, and research.
Drug Research > Drug Discovery & Development > News
Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals
Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI
Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.
Drug Research > Drug Discovery & Development > News
HitGen, Takeda enter DNA-encoded library based drug discovery research collaboration
HitGen announced that the company has entered into a research collaboration with Takeda Pharmaceutical Company to discover novel small molecule leads for multiple targets in Takeda’s therapeutic areas of interest.
Drug Research > Drug Discovery & Development > News
Janssen scraps hepatitis C development program
By PBR Staff Writer
Janssen Sciences Ireland UC has scrapped its ongoing hepatitis C development program citing the growing number of therapies available for treating the disease effectively.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, Gubra to develop next generation obesity treatments
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.
Drug Research > Drug Discovery & Development > News
European Investment Bank grants €75m funding for Evotec
Evotec and the European Investment Bank (EIB) announced that the EIB has granted Evotec an unsecured loan facility of up to €75m to support Evotec's Innovate strategy.
Drug Research > Drug Discovery & Development > News
GSK exercises option on phase I/II NY-ESO T-cell therapy
GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).
Drug Research > Drug Discovery & Development > News
Jazz Pharmaceuticals, ImmunoGen to collaborate on hematology-related ADC products
By PBR Staff Writer
Ireland-based Jazz Pharmaceuticals has partnered with ImmunoGen to develop and commercialize the US biotechnology company’s two early-stage, hematology-related antibody-drug conjugate (ADC) products.
Drug Research > Drug Discovery & Development > News
CSL Behring to buy US biotechnology firm Calimmune
By PBR Staff Writer
CSL Behring, the US subsidiary of Australia-based CSL has agreed to acquire Calimmune, an American biotechnology company focused on developing ex vivo hematopoietic stem cell (HSC) gene therapy.
Drug Research > Drug Discovery & Development > News
Regenxbio to buy US firm Dimension Therapeutics
By PBR Staff Writer
Gene therapy firm Regenxbio has signed an agreement to acquire US-based firm Dimension Therapeutics.
Drug Research > Drug Discovery & Development > News
Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody
Ligand Pharmaceuticals will get a payment of $2m from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other selected territories.
Drug Research > Drug Discovery & Development > News
1-15 of 4483 results